Hepatocellular carcinoma: Perfusion quantification with dynamic contrast-enhanced MRI

American Journal of Roentgenology

Volumn 201, Issue 4, 2013, Pages 795-800

  Taouli, Bachir ^a,b   Johnson, R Scott ^b   Hajdu, Cristina H ^b   Oei, Marcel T H ^b,c   Merad, Miriam ^a   Yee, Herman ^a   Rusinek, Henry ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemoembolization; Dynamic contrastenhanced MRI; Hepatocellular carcinoma; Perfusion

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE;

ABDOMINAL AORTA; ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; CANCER SIZE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONSENSUS; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMODYNAMIC PARAMETERS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SOFTWARE; LABORATORY DEVICE; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; MEAN TRANSIT TIME; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; POWER INJECTOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84886415305     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9798     Document Type: Article

References (38)

1. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986; 6:259-266
2. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001; 116:838-845
3. Dhar DK, Naora H, Yamanoi A, et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 2002; 22:379-386
4. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991; 47:219-223
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039
6. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32:2413-2422
7. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127:S179-S188
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
9. Padhani AR. Dynamic contrast-enhanced MRI studies in human tumours. Br J Radiol 1999; 72:427-431
10. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16:407-422
11. Parker GJ, Suckling J, Tanner SF, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997; 7:564-574
12. Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 2002; 47:135-142
13. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229:409-414
14. Van Beers BE, Materne R, Annet L, et al. Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrast-enhanced MRI in the rabbit. Magn Reson Med 2003; 49:692-699
15. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008; 246:926-934
16. Abdullah SS, Pialat JB, Wiart M, et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008; 28:390-395
17. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010; 31:589-600
18. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243:736-743
19. Ippolito D, Sironi S, Pozzi M, et al. Perfusion computed tomographic assessment of early hepatocellular carcinoma in cirrhotic liver disease: initial observations. J Comput Assist Tomogr 2008; 32:855-858
20. Ippolito D, Sironi S, Pozzi M, et al. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol 2010; 73:148-152
21. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964
22. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR 2004; 183:713-719
23. Totman JJ, O'Gorman RL, Kane PA, Karani JB. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 2005; 78:105-109
24. Miyazaki K, Collins DJ, Walker-Samuel S, et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008; 18:1414-1421
25. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47:11-17
26. Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009; 20:1589-1595
27. Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18:2192-2199
28. Wang D, Gaba RC, Jin B, et al. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011; 18:828-836
29. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022
30. Jones RA, Easley K, Little SB, Scherz H, Kirsch AJ, Grattan-Smith JD. Dynamic contrast-enhanced MR urography in the evaluation of pediatric hydronephrosis. Part. 1 Functional assessment. AJR 2005; 185:1598-1607
31. Bokacheva L, Rusinek H, Chen Q, et al. Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 2007; 57:1012-1018
32. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30:17-25
33. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293-4300
34. Van Beers BE, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR 2001; 176:667-673
35. Ronot M, Asselah T, Paradis V, et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 2010; 256:135-142
36. Chen BB, Hsu CY, Yu CW, et al. Dynamic contrastenhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol 2012; 22:171-180
37. Larsson HB, Fritz-Hansen T, Rostrup E, Sondergaard L, Ring P, Henriksen O. Myocardial perfusion modeling using MRI. Magn Reson Med 1996; 35:716-726
38. Koh TS, Thng CH, Lee PS, et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008; 249:307-320